X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-18 | CRMD | Cormedix Inc. | Todisco Joseph | CEO | S - Sale+OE | $12.00 | -30,000 | 509,496 | -6% | -$360,000 | |||||
| D | 2025-12-17 | ROIV | Roivant Sciences Ltd. | Sukhatme Mayukh | Pres, CIO | S - Sale+OE | $23.09 | -26,831 | 18,836,547 | 0% | -$619,528 | |||||
2025-12-19 | TYRA | Tyra Biosciences, Inc. | More Robert J | Dir | S - Sale | $25.00 | -10,000 | 3,823,425 | 0% | -$250,000 | ||||||
| D | 2025-12-17 | MNKD | Mannkind Corp | Castagna Michael | CEO | S - Sale+OE | $6.01 | -65,804 | 2,504,792 | -3% | -$395,482 | |||||
| M | 2025-12-17 | SION | Sionna Therapeutics, Inc. | Orbimed Advisors LLC | Dir | S - Sale | $44.49 | -1,875 | 3,595,011 | 0% | -$83,428 | |||||
| M | 2025-12-17 | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Dir | S - Sale | $44.49 | -1,875 | 3,595,011 | 0% | -$83,428 | |||||
2025-12-17 | HYPD | Hyperion Defi, Inc. | Walters Happy David | Dir | P - Purchase | $3.02 | +61,930 | 111,930 | +124% | +$187,152 | ||||||
2025-12-17 | ARWR | Arrowhead Pharmaceuticals, Inc. | Anzalone Christopher Richard | CEO | S - Sale | $64.04 | -85,000 | 3,831,957 | -2% | -$5,443,462 | ||||||
| D | 2025-12-19 | ORKA | Oruka Therapeutics, Inc. | Goncalves Joana | Chief Medical Officer | S - Sale+OE | $30.61 | -7,000 | 1,518 | -82% | -$214,293 | |||||
| M | 2025-12-17 | RPRX | Royalty Pharma Plc | Lloyd George W. | EVP, Investments, CLO | S - Sale | $38.55 | -110,000 | 779,915 | -12% | -$4,240,333 | |||||
| DM | 2025-12-17 | PTCT | Ptc Therapeutics, Inc. | Pauwels Eric | CHIEF BUSINESS OFFICER | S - Sale+OE | $75.40 | -43,492 | 70,373 | -38% | -$3,279,275 | |||||
2025-12-19 | XERS | Xeris Biopharma Holdings, Inc. | Johnson John | Dir | S - Sale | $7.22 | -135,400 | 698,083 | -16% | -$977,019 | ||||||
2025-12-19 | SVRA | Savara Inc | Ramsay David A | Dir | S - Sale | $6.06 | -20,000 | 2,533,642 | -1% | -$121,220 | ||||||
2025-12-17 | ADTX | Aditxt, Inc. | Brady Brian Michael | Dir | S - Sale | $1.75 | -1 | 3 | -25% | -$2 | ||||||
2025-12-18 | ANIP | Ani Pharmaceuticals Inc | Davis Krista | SVP, CHRO | S - Sale | $82.40 | -1,622 | 58,564 | -3% | -$133,653 | ||||||
| D | 2025-12-18 | UTHR | United Therapeutics Corp | Thompson Tommy G | Dir | S - Sale+OE | $500.59 | -910 | 22,480 | -4% | -$455,533 | |||||
| DM | 2025-12-17 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $505.38 | -10,000 | 639,489 | -2% | -$5,053,778 | |||||
| D | 2025-12-18 | KURA | Kura Oncology, Inc. | Burrows Francis | Chief Scientific Officer | S - Sale+OE | $9.78 | -23,726 | 33,735 | -41% | -$231,931 | |||||
| D | 2025-12-18 | MIRM | Mirum Pharmaceuticals, Inc. | Ramasastry Saira | Dir | S - Sale+OE | $69.73 | -2,000 | 0 | -100% | -$139,460 | |||||
| D | 2025-12-18 | VTYX | Ventyx Biosciences, Inc. | Mohan Raju | CEO, Pres | S - Sale+OE | $7.72 | -47,345 | 2,372,863 | -2% | -$365,461 | |||||
| D | 2025-12-18 | VTYX | Ventyx Biosciences, Inc. | Nuss John | Chief Scientific Officer | S - Sale+OE | $7.72 | -12,675 | 489,481 | -3% | -$97,840 | |||||
| D | 2025-12-18 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $166.97 | -10,699 | 588,335 | -2% | -$1,786,457 | |||||
| D | 2025-12-17 | GALT | Galectin Therapeutics Inc | Lewis Joel | Pres, CEO | S - Sale+OE | $7.06 | -7,829 | 834,592 | -1% | -$55,241 | |||||
| D | 2025-12-17 | GALT | Galectin Therapeutics Inc | Jamil Khurram | Chief Medical Officer | S - Sale+OE | $7.04 | -19,442 | 0 | -100% | -$136,872 | |||||
| D | 2025-12-18 | SUPN | Supernus Pharmaceuticals, Inc. | Bhatt Padmanabh P. | SVP of IP, CSO | S - Sale+OE | $44.44 | -710 | 14,508 | -5% | -$31,552 | |||||
2025-12-17 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $40.37 | +2,735 | 384,530 | +1% | +$110,412 | ||||||
| D | 2025-12-17 | PVLA | Palvella Therapeutics, Inc. | Goin Kathleen | COO | S - Sale+OE | $96.47 | -4,302 | 0 | -100% | -$415,023 | |||||
| D | 2025-12-17 | GALT | Galectin Therapeutics Inc | Shlevin Harold H. | Dir | S - Sale+OE | $7.04 | -24,499 | 6,500 | -79% | -$172,424 | |||||
2025-12-18 | MNPR | Monopar Therapeutics | Klausner Arthur J | Dir | S - Sale | $67.15 | -5,121 | 8,762 | -37% | -$343,889 | ||||||
2025-12-17 | HYPD | Hyperion Defi, Inc. | Geltzeiler Michael S | Dir | P - Purchase | $3.01 | +30,000 | 88,015 | +52% | +$90,210 | ||||||
2025-12-17 | RNXT | Renovorx, Inc. | Bagai Shaun | CEO | P - Purchase | $0.85 | +5,000 | 335,040 | +2% | +$4,262 | ||||||
2025-12-18 | GLSI | Greenwich Lifesciences, Inc. | Patel Snehal | CEO, CFO, 10% | P - Purchase | $12.62 | +4,100 | 5,592,202 | 0% | +$51,742 | ||||||
2025-12-16 | SRPT | Sarepta Therapeutics, Inc. | Estepan Ian Michael | COO | S - Sale | $22.31 | -13,187 | 193,300 | -6% | -$294,202 | ||||||
| M | 2025-12-16 | ROIV | Roivant Sciences Ltd. | Gold Daniel Allen | Dir | S - Sale | $23.05 | -1,694,614 | 16,353,113 | -9% | -$39,065,213 | |||||
| M | 2025-12-16 | ROIV | Roivant Sciences Ltd. | Manchester Keith S | Dir | S - Sale | $23.05 | -1,694,614 | 16,353,113 | -9% | -$39,065,213 | |||||
| M | 2025-12-16 | ROIV | Roivant Sciences Ltd. | Qvt Financial LP | Director by Deputization | S - Sale | $23.05 | -1,694,614 | 16,353,113 | -9% | -$39,065,213 | |||||
2025-12-17 | IRON | Disc Medicine, Inc. | Bitterman Kevin | Dir | S - Sale | $91.47 | -754 | 14,013 | -5% | -$68,968 | ||||||
| D | 2025-12-18 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale+OE | $17.90 | -3,760 | 50,897 | -7% | -$67,314 | |||||
| M | 2025-12-16 | MRUS | Merus N.V. | Genmab A/S | 10% | P - Purchase | $97.00 | +271,547 | 71,734,624 | 0% | +$26,340,059 | |||||
| M | 2025-12-16 | RCUS | Arcus Biosciences, Inc. | Tang Carolyn C. | GC | S - Sale | $22.01 | -14,468 | 124,734 | -10% | -$318,496 | |||||
| M | 2025-12-16 | RCUS | Arcus Biosciences, Inc. | Markus Richard | Chief Medical Officer | S - Sale | $22.01 | -9,546 | 65,647 | -13% | -$210,144 | |||||
| M | 2025-12-16 | RCUS | Arcus Biosciences, Inc. | Azoy Alexander | Chief Accounting Officer | S - Sale | $22.13 | -8,832 | 18,531 | -32% | -$195,434 | |||||
| M | 2025-12-16 | RCUS | Arcus Biosciences, Inc. | Goeltz II Robert C. | CFO | S - Sale | $22.01 | -12,662 | 74,476 | -15% | -$278,739 | |||||
| M | 2025-12-16 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | COO | S - Sale | $22.01 | -21,208 | 193,024 | -10% | -$466,870 | |||||
| M | 2025-12-16 | RCUS | Arcus Biosciences, Inc. | Jaen Juan C. | Pres | S - Sale | $22.01 | -21,208 | 1,300,075 | -2% | -$466,870 | |||||
| M | 2025-12-16 | RCUS | Arcus Biosciences, Inc. | Rosen Terry J | CEO | S - Sale | $22.01 | -54,691 | 2,194,809 | -2% | -$1,203,959 | |||||
| D | 2025-12-17 | AMPH | Amphastar Pharmaceuticals, Inc. | Zhou Rong | SENIOR EVP, PRODUCTION CENTER | S - Sale+OE | $26.20 | -9,787 | 242,711 | -4% | -$256,379 | |||||
| M | 2025-12-03 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% | S - Sale | $6.69 | -257,795 | 393,150 | -40% | -$1,725,735 | |||||
2025-12-18 | IMNM | Immunome Inc. | Siegall Clay B | Pres, CEO | P - Purchase | $21.50 | +46,511 | 853,247 | +6% | +$999,987 | ||||||
2025-12-16 | VSTM | Verastem, Inc. | Stuglik Brian M | Dir | S - Sale | $9.14 | -592 | 101,147 | -1% | -$5,411 | ||||||
2025-12-16 | VSTM | Verastem, Inc. | Paterson Dan | Pres, CEO | S - Sale | $9.14 | -393 | 410,425 | 0% | -$3,592 | ||||||
2025-12-16 | VSTM | Verastem, Inc. | Gagnon Robert E. | Dir | S - Sale | $9.14 | -283 | 41,678 | -1% | -$2,587 | ||||||
2025-12-16 | ZLAB | Zai Lab Ltd | Edmondson Frazor Titus III | GC | S - Sale | $17.14 | -8,651 | 19,086 | -31% | -$148,278 | ||||||
2025-12-16 | ORGO | Organogenesis Holdings Inc. | Nussdorf Glenn H | Dir | S - Sale | $5.14 | -200,000 | 11,748,560 | -2% | -$1,027,060 | ||||||
| DM | 2025-12-16 | ANAB | Anaptysbio, Inc | Loumeau Eric J | GC | S - Sale+OE | $45.38 | -22,641 | 8,947 | -72% | -$1,027,425 | |||||
| D | 2025-12-16 | ANAB | Anaptysbio, Inc | Mulroy Dennis | CFO | S - Sale+OE | $44.85 | -15,725 | 9,401 | -63% | -$705,333 | |||||
2025-12-17 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO | S - Sale | $29.64 | -10,916 | 680,537 | -2% | -$323,508 | ||||||
2025-12-17 | ESPR | Esperion Therapeutics, Inc. | Koenig Sheldon L. | Pres, CEO | S - Sale | $3.67 | -48,244 | 1,470,587 | -3% | -$177,200 | ||||||
2025-12-17 | ESPR | Esperion Therapeutics, Inc. | Halladay Benjamin | CFO | S - Sale | $3.67 | -7,337 | 467,525 | -2% | -$26,905 | ||||||
2025-12-17 | ESPR | Esperion Therapeutics, Inc. | Looker Benjamin | GC | S - Sale | $3.67 | -6,517 | 385,905 | -2% | -$23,898 | ||||||
2025-12-16 | APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | GC | S - Sale | $24.49 | -5,000 | 163,866 | -3% | -$122,450 | ||||||
2025-12-16 | TEVA | Teva Pharmaceutical Industries Ltd | Weiss Amir | Chief Accounting Officer | S - Sale | $30.20 | -12,300 | 5,650 | -69% | -$371,504 | ||||||
2025-12-16 | TEVA | Teva Pharmaceutical Industries Ltd | Mignone Roberto | Dir | S - Sale | $30.24 | -77,400 | 472,915 | -14% | -$2,340,646 | ||||||
2025-12-16 | APLT | Applied Therapeutics, Inc. | Kanter Stacy J. | Dir | S - Sale | $0.11 | -43,000 | 65,000 | -40% | -$4,816 | ||||||
2025-12-16 | GALT | Galectin Therapeutics Inc | 10X Fund, L.P. | 10% | S - Sale | $6.66 | -30,681 | 5,614,457 | -1% | -$204,335 | ||||||
| D | 2025-12-15 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO | S - Sale+OE | $21.68 | -1,740,000 | 17,287,081 | -9% | -$37,723,200 | |||||
| D | 2025-12-16 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $2.96 | -3,227 | 0 | -100% | -$9,562 | |||||
| D | 2025-12-16 | ORIC | Oric Pharmaceuticals, Inc. | Multani Pratik S | Chief Medical Officer | S - Sale+OE | $9.06 | -10,720 | 68,149 | -14% | -$97,129 | |||||
| D | 2025-12-16 | ORIC | Oric Pharmaceuticals, Inc. | Piscitelli Dominic | CFO | S - Sale+OE | $9.06 | -10,720 | 68,148 | -14% | -$97,127 | |||||
| D | 2025-12-16 | ORIC | Oric Pharmaceuticals, Inc. | Chacko Jacob | Pres, CEO | S - Sale+OE | $9.06 | -33,374 | 581,711 | -5% | -$302,368 | |||||
| M | 2025-12-15 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $1.08 | -48,171 | 2,841,957 | -2% | -$51,951 | |||||
| D | 2025-12-15 | FOLD | Amicus Therapeutics, Inc. | Campbell Bradley L | Pres, CEO | S - Sale+OE | $10.86 | -77,926 | 1,129,782 | -6% | -$846,011 | |||||
2025-12-15 | FOLD | Amicus Therapeutics, Inc. | Clark David Michael | Chief People Officer | S - Sale | $11.00 | -25,643 | 271,332 | -9% | -$282,073 | ||||||
| D | 2025-12-15 | ARQT | Arcutis Biotherapeutics, Inc. | Burnett Patrick | See Remarks | S - Sale+OE | $28.94 | -11,500 | 98,307 | -10% | -$332,851 | |||||
2025-12-16 | RPRX | Royalty Pharma Plc | Urist Marshall | EVP, Research, Investments | S - Sale | $38.32 | -20,000 | 166,418 | -11% | -$766,420 | ||||||
2025-12-15 | RPRX | Royalty Pharma Plc | Coyne Terrance P. | EVP, CFO | S - Sale | $38.36 | -69,582 | 620,560 | -10% | -$2,669,172 | ||||||
| D | 2025-12-12 | HRMY | Harmony Biosciences Holdings, Inc. | Dayno Jeffrey M. | Pres, CEO | S - Sale+OE | $40.11 | -25,933 | 0 | -100% | -$1,040,103 | |||||
| M | 2025-12-15 | ONC | Beone Medicines Ltd. | Oyler John | CEO | S - Sale | $306.59 | -100,000 | 51,196,357 | 0% | -$30,659,419 | |||||
| D | 2025-12-15 | KNSA | Kiniksa Pharmaceuticals International, Plc | Quart Barry D | Dir | S - Sale+OE | $41.51 | -20,129 | 12,546 | -62% | -$835,555 | |||||
| D | 2025-12-15 | KNSA | Kiniksa Pharmaceuticals International, Plc | Tessari Eben | COO | S - Sale+OE | $41.56 | -12,048 | 16,666 | -42% | -$500,715 | |||||
2025-12-15 | LFVN | Lifevantage Corp | Lewis Darwin | Dir | P - Purchase | $6.54 | +805 | 131,553 | +1% | +$5,265 | ||||||
2025-12-16 | RZLT | Rezolute, Inc. | Hogenhuis Wladimir | Dir | P - Purchase | $1.69 | +5,650 | 119,675 | +5% | +$9,549 | ||||||
2025-12-16 | RZLT | Rezolute, Inc. | Roberts Brian Kenneth | Chief Medical Officer | P - Purchase | $1.70 | +28,000 | 323,852 | +9% | +$47,600 | ||||||
2025-12-15 | FULC | Fulcrum Therapeutics, Inc. | Oltmans Curtis Gale | GC | S - Sale | $12.92 | -3,452 | 10,252 | -25% | -$44,600 | ||||||
| D | 2025-12-15 | VERA | Vera Therapeutics, Inc. | Turner William D. | Chief Regulatory Officer | S - Sale+OE | $50.08 | -10,000 | 22,500 | -31% | -$500,767 | |||||
2025-12-16 | RNXT | Renovorx, Inc. | Agah Ramtin | Chief Medical Officer | P - Purchase | $0.85 | +12,000 | 778,460 | +2% | +$10,200 | ||||||
| DM | 2025-12-12 | IRON | Disc Medicine, Inc. | Bitterman Kevin | Dir | S - Sale+OE | $91.56 | -184,123 | 14,161 | -93% | -$16,858,639 | |||||
2025-12-15 | IRON | Disc Medicine, Inc. | Savage William Jacob | Chief Medical Officer | S - Sale | $91.22 | -13,093 | 75,702 | -15% | -$1,194,372 | ||||||
| DM | 2025-12-12 | MNKD | Mannkind Corp | Castagna Michael | CEO | S - Sale+OE | $6.00 | -42,116 | 2,504,792 | -2% | -$252,696 | |||||
| D | 2025-12-12 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $3.26 | -1,700 | 0 | -100% | -$5,541 | |||||
2025-12-12 | LGND | Ligand Pharmaceuticals Inc | Espinoza Octavio | CFO | S - Sale | $188.31 | -1,804 | 26,186 | -6% | -$339,711 | ||||||
2025-12-15 | SILO | Silo Pharma, Inc. | Weisblum Eric | CEO | P - Purchase | $0.42 | +5,000 | 216,932 | +2% | +$2,075 | ||||||
| D | 2025-12-15 | BBIO | Bridgebio Pharma, Inc. | Kumar Neil | CEO | S - Sale+OE | $74.64 | -30,011 | 5,542,909 | -1% | -$2,239,902 | |||||
2025-12-12 | CLRB | Cellectar Biosciences, Inc. | Neis John | Dir | S - Sale | $3.70 | -198 | 10 | -95% | -$732 | ||||||
2025-12-15 | SXTP | 60 Degrees Pharmaceuticals, Inc. | Dow Geoffrey S | Pres, CEO | P - Purchase | $0.80 | +9,670 | 59,618 | +19% | +$7,759 | ||||||
| D | 2025-12-15 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $495.36 | -3,517 | 8,142 | -30% | -$1,742,193 | |||||
| DM | 2025-12-15 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $494.09 | -8,000 | 639,489 | -1% | -$3,952,689 | |||||
2025-12-15 | RAPP | Rapport Therapeutics, Inc. | Bredt David | Chief Scientific Officer | S - Sale | $30.02 | -8,500 | 392,642 | -2% | -$255,130 | ||||||
| D | 2025-12-12 | CPRX | Catalyst Pharmaceuticals, Inc. | Harper Molly | Dir | S - Sale+OE | $23.25 | -26,746 | 2,360 | -92% | -$621,920 | |||||
| D | 2025-12-15 | BCAX | Bicara Therapeutics Inc. | Cohlhepp Ryan | Pres, COO | S - Sale+OE | $18.68 | -12,500 | 189,141 | -6% | -$233,548 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |